BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

681 related articles for article (PubMed ID: 26978724)

  • 1. Performance of Common Disease Activity Markers as a Reflection of Inflammatory Burden in Ulcerative Colitis.
    Brandse JF; Bennink RJ; van Eeden S; Löwenberg M; van den Brink GR; DʼHaens GR
    Inflamm Bowel Dis; 2016 Jun; 22(6):1384-90. PubMed ID: 26978724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes.
    Schoepfer AM; Beglinger C; Straumann A; Trummler M; Renzulli P; Seibold F
    Inflamm Bowel Dis; 2009 Dec; 15(12):1851-8. PubMed ID: 19462421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis.
    Lee SH; Kim MJ; Chang K; Song EM; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK; Ye BD
    BMC Gastroenterol; 2017 Oct; 17(1):110. PubMed ID: 29061121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Positron Emission Tomography in Assessing Disease Activity in Ulcerative Colitis: Comparison with Biomarkers.
    Berry N; Sinha SK; Bhattacharya A; Prasad KK; Vaishnavi C; Vaiphei K; Samanta J; Prasada R; Dhaka N; Kochhar R
    Dig Dis Sci; 2018 Jun; 63(6):1541-1550. PubMed ID: 29564671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of Fecal Markers with Magnifying Endoscopic Stratification in Patients with Ulcerative Colitis Who Are in Clinical Remission.
    Mine S; Takeshima F; Akazawa Y; Matsushima K; Minami H; Yamaguchi N; Ohnita K; Isomoto H; Nakao K
    Digestion; 2018; 97(1):82-89. PubMed ID: 29393146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis.
    Urushikubo J; Yanai S; Nakamura S; Kawasaki K; Akasaka R; Sato K; Toya Y; Asakura K; Gonai T; Sugai T; Matsumoto T
    World J Gastroenterol; 2018 Oct; 24(38):4384-4392. PubMed ID: 30344422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
    Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
    World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical, endoscopic and histological correlation and measures of association in ulcerative colitis.
    Fluxá D; Simian D; Flores L; Ibáñez P; Lubascher J; Figueroa C; Kronberg U; Pizarro G; Castro M; Piottante A; Vial MT; Quera R
    J Dig Dis; 2017 Nov; 18(11):634-641. PubMed ID: 28949435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis.
    Carlsen K; Riis LB; Elsberg H; Maagaard L; Thorkilgaard T; Sørbye SW; Jakobsen C; Wewer V; Florholmen J; Goll R; Munkholm P
    Scand J Gastroenterol; 2018; 53(7):825-830. PubMed ID: 29968483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
    Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How disease extent can be included in the endoscopic activity index of ulcerative colitis: the panMayo score, a promising scoring system.
    Bálint A; Farkas K; Szepes Z; Nagy F; Szűcs M; Tiszlavicz L; Bor R; Milassin Á; Rutka M; Fábián A; Molnár T
    BMC Gastroenterol; 2018 Jan; 18(1):7. PubMed ID: 29310593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes.
    Schoepfer AM; Beglinger C; Straumann A; Safroneeva E; Romero Y; Armstrong D; Schmidt C; Trummler M; Pittet V; Vavricka SR
    Inflamm Bowel Dis; 2013 Feb; 19(2):332-41. PubMed ID: 23328771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Level of Fecal Calprotectin Correlates With Endoscopic and Histologic Inflammation and Identifies Patients With Mucosal Healing in Ulcerative Colitis.
    Theede K; Holck S; Ibsen P; Ladelund S; Nordgaard-Lassen I; Nielsen AM
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1929-36.e1. PubMed ID: 26051392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients.
    Lobatón T; Bessissow T; De Hertogh G; Lemmens B; Maedler C; Van Assche G; Vermeire S; Bisschops R; Rutgeerts P; Bitton A; Afif W; Marcus V; Ferrante M
    J Crohns Colitis; 2015 Oct; 9(10):846-52. PubMed ID: 26116558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients.
    Lin WC; Wong JM; Tung CC; Lin CP; Chou JW; Wang HY; Shieh MJ; Chang CH; Liu HH; Wei SC;
    World J Gastroenterol; 2015 Dec; 21(48):13566-73. PubMed ID: 26730169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
    Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
    Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis-a Prospective Analysis.
    Walsh A; Kormilitzin A; Hinds C; Sexton V; Brain O; Keshav S; Uhlig H; Geddes J; Goodwin G; Peters M; Collins G; Travis S
    J Crohns Colitis; 2019 Mar; 13(4):424-430. PubMed ID: 30445625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.
    Ricanek P; Brackmann S; Perminow G; Lyckander LG; Sponheim J; Holme O; Høie O; Rydning A; Vatn MH;
    Scand J Gastroenterol; 2011 Sep; 46(9):1081-91. PubMed ID: 21619483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease.
    Samant H; Desai D; Abraham P; Joshi A; Gupta T; Dherai A; Ashavaid T
    Indian J Gastroenterol; 2015 Nov; 34(6):431-5. PubMed ID: 26589229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.